DE2513797C2 - Pharmazeutische zusammensetzung - Google Patents

Pharmazeutische zusammensetzung

Info

Publication number
DE2513797C2
DE2513797C2 DE2513797A DE2513797A DE2513797C2 DE 2513797 C2 DE2513797 C2 DE 2513797C2 DE 2513797 A DE2513797 A DE 2513797A DE 2513797 A DE2513797 A DE 2513797A DE 2513797 C2 DE2513797 C2 DE 2513797C2
Authority
DE
Germany
Prior art keywords
diisopropylphenol
composition
sterile
solution
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2513797A
Other languages
German (de)
English (en)
Other versions
DE2513797A1 (de
Inventor
John B Glen
Roger James
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Original Assignee
Imperial Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Chemical Industries Ltd filed Critical Imperial Chemical Industries Ltd
Publication of DE2513797A1 publication Critical patent/DE2513797A1/de
Application granted granted Critical
Publication of DE2513797C2 publication Critical patent/DE2513797C2/de
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE2513797A 1974-03-28 1975-03-27 Pharmazeutische zusammensetzung Expired DE2513797C2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1373974A GB1472793A (en) 1974-03-28 1974-03-28 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
DE2513797A1 DE2513797A1 (de) 1975-10-09
DE2513797C2 true DE2513797C2 (de) 1987-07-30

Family

ID=10028495

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2513797A Expired DE2513797C2 (de) 1974-03-28 1975-03-27 Pharmazeutische zusammensetzung

Country Status (22)

Country Link
US (2) US4056635A (US07902200-20110308-C00004.png)
JP (1) JPS50154410A (US07902200-20110308-C00004.png)
AU (1) AU502164B2 (US07902200-20110308-C00004.png)
BE (1) BE827290A (US07902200-20110308-C00004.png)
CA (1) CA1038764A (US07902200-20110308-C00004.png)
DE (1) DE2513797C2 (US07902200-20110308-C00004.png)
DK (1) DK128675A (US07902200-20110308-C00004.png)
DO (1) DOP1980002892A (US07902200-20110308-C00004.png)
FI (1) FI750941A (US07902200-20110308-C00004.png)
FR (1) FR2265357B1 (US07902200-20110308-C00004.png)
GB (1) GB1472793A (US07902200-20110308-C00004.png)
HK (1) HK34380A (US07902200-20110308-C00004.png)
IE (1) IE40839B1 (US07902200-20110308-C00004.png)
IL (1) IL46899A (US07902200-20110308-C00004.png)
KE (1) KE3052A (US07902200-20110308-C00004.png)
MY (1) MY8100111A (US07902200-20110308-C00004.png)
NL (2) NL183079C (US07902200-20110308-C00004.png)
NO (1) NO751076L (US07902200-20110308-C00004.png)
NZ (1) NZ177023A (US07902200-20110308-C00004.png)
PH (1) PH13553A (US07902200-20110308-C00004.png)
SE (1) SE7503542L (US07902200-20110308-C00004.png)
ZA (1) ZA751806B (US07902200-20110308-C00004.png)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19509828A1 (de) * 1994-03-22 1996-09-19 Zeneca Ltd Pharmazeutische Zusammensetzungen
US6634576B2 (en) 2000-08-31 2003-10-21 Rtp Pharma Inc. Milled particles
US7939106B2 (en) 1998-11-20 2011-05-10 Jagotec Ag Process for preparing a rapidly dispersing solid drug dosage form
US8206746B2 (en) 1996-08-22 2012-06-26 Jagotec Ag Microparticles of water-insoluble substances
US8415329B1 (en) 1998-05-29 2013-04-09 Jagotec Ag Thermoprotected compositions and process for terminal steam sterilization of microparticle preparations
US8703202B2 (en) 2000-09-20 2014-04-22 Jagotec Ag Coated tablets

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6005001A (en) * 1991-05-20 1999-12-21 Novartis Ag (Formerly Sandoz Ag) Pharmaceutical composition
HU223343B1 (hu) * 1991-05-20 2004-06-28 Novartis Ag. Allil-amin-származékot tartalmazó gyógyászati készítmények és eljárás azok előállítására
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US20020173547A1 (en) 1994-03-22 2002-11-21 Jones Christopher Buchan Pharmaceuticals compositions
US5731356A (en) * 1994-03-22 1998-03-24 Zeneca Limited Pharmaceutical compositions of propofol and edetate
MY113046A (en) * 1994-03-22 2001-11-30 Astrazeneca Uk Ltd Pharmaceutical compositions
IT1269977B (it) 1994-07-01 1997-04-16 Archimica Spa Purificazione del propofol
IT1270093B (it) * 1994-09-28 1997-04-28 Zambon Spa Processo per la purificazione di 2,6-diisopropilfenolo
CN100457086C (zh) * 1995-03-17 2009-02-04 曾尼卡有限公司 无菌医药组合物
CN1106192C (zh) * 1995-03-17 2003-04-23 曾尼卡有限公司 含2,6－二异丙基苯酚和乙二胺四乙酸盐的水包油型乳液
WO1997010814A1 (en) * 1995-09-18 1997-03-27 Vesifact Ag Propofol nanodispersions
CA2234957C (en) 1995-10-17 2006-12-19 Inge B. Henriksen Insoluble drug delivery
US5637625A (en) * 1996-03-19 1997-06-10 Research Triangle Pharmaceuticals Ltd. Propofol microdroplet formulations
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
CH692322A5 (it) * 1997-05-26 2002-05-15 Westy Ag Formulazione iniettabile limpida di Propofol.
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
DE19757224A1 (de) 1997-12-22 1999-07-01 Bayer Ag Verfahren und Vorrichtung zur in-situ-Formulierung einer Arzneistofflösung zur parenteralen Applikation
NZ505948A (en) * 1998-02-10 2003-10-31 Sicor Inc Propofol composition containing sulfite as a preservative to prevent bacterial growth of Staphylococcus, Escherichia, Pseudomonas and Candida
ATE241363T1 (de) * 1998-02-11 2003-06-15 Rtp Pharma Corp Ungesättigte fettsäure und steroide enthaltende kombinationspräparate zur behandlung von entzündungen
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
ATE252889T1 (de) 1998-08-19 2003-11-15 Skyepharma Canada Inc Injizierbare wässerige propofoldispersionen
US6150423A (en) * 1998-10-15 2000-11-21 Phoenix Scientific, Inc. Propofol-based anesthetic and method of making same
US6028108A (en) * 1998-10-22 2000-02-22 America Home Products Corporation Propofol composition comprising pentetate
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6177477B1 (en) * 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6100302A (en) * 1999-04-05 2000-08-08 Baxter International Inc. Propofol formulation with enhanced microbial characteristics
JP2003502363A (ja) * 1999-06-21 2003-01-21 コンイル ファーマシューティカル カンパニー、リミテッド プロポフォールを含有する静脈内注射用麻酔剤組成物
GB2359747B (en) * 2000-02-29 2002-04-24 Maelor Pharmaceuticals Ltd Anaesthetic formulations
KR100386397B1 (ko) * 2000-04-19 2003-06-02 센츄론(주) 투명한 프로포폴 주사제
US6682761B2 (en) 2000-04-20 2004-01-27 Rtp Pharma, Inc. Water-insoluble drug particle process
IL153457A0 (en) 2000-06-16 2003-07-06 Skyepharma Canada Inc Improved injectable dispersions of propofol
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US6869617B2 (en) * 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
CN1273112C (zh) * 2001-02-22 2006-09-06 斯凯伊药品加拿大公司 具有减少进食－禁食作用的贝特－它汀组合
JP4127757B2 (ja) * 2001-08-21 2008-07-30 株式会社エヌ・ティ・ティ・ドコモ 無線通信システム、通信端末装置、及びバースト信号送信方法
GB0120702D0 (en) * 2001-08-24 2001-10-17 Maelor Pharmaceuticals Ltd Anaesthetic formulations
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
JP2005504090A (ja) 2001-09-26 2005-02-10 バクスター・インターナショナル・インコーポレイテッド 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製
CA2459125A1 (en) 2001-09-26 2003-04-03 Theravance, Inc. Substituted phenol compounds useful for anesthesia and sedation
GB0124071D0 (en) * 2001-10-08 2001-11-28 Kbig Ltd Improvement in the administration of high boiling point aneasthetics
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
JP3931680B2 (ja) * 2002-02-18 2007-06-20 株式会社日本自動車部品総合研究所 車両の直進判別装置
US7550155B2 (en) * 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
CA2494297C (en) * 2002-07-29 2011-10-18 Transform Pharmaceuticals, Inc. Aqueous 2,6-diisopropylphenol pharmaceutical compositions
US20040220283A1 (en) * 2002-07-29 2004-11-04 Transform Pharmaceuticals, Inc. Aqueous 2,6-diisopropylphenol pharmaceutical compositions
EP1556022A4 (en) * 2002-10-29 2010-03-10 Transform Pharmaceuticals Inc AQUEOUS PHARMACEUTICAL COMPOSITIONS 2,6-DIISOPROPYLPHENOL
WO2004039326A2 (en) * 2002-10-29 2004-05-13 Transform Pharmaceuticals, Inc. Propofol with cysteine
NZ539834A (en) * 2002-11-26 2007-08-31 Maruishi Pharma Isoindoline derivatives
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US8476010B2 (en) 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
US8546453B2 (en) 2003-08-14 2013-10-01 Rensheng Zhang Propofol compositions and methods for reducing pain associated with propofol injection
ITMI20032054A1 (it) * 2003-10-22 2005-04-23 Monteres S R L Processo per la preparazione di sospensioni farmaceutiche da inalare.
EA010885B1 (ru) 2003-12-08 2008-12-30 Бентли Фармасьютикалз, Инк. Фармацевтические композиции и способы лечения инсулином
WO2005077337A2 (en) * 2004-02-05 2005-08-25 Baxter International Inc. Dispersions prepared by use of self-stabilizing agents
MX2007015183A (es) * 2005-06-14 2008-02-19 Baxter Int Formulaciones farmaceuticas para minimizar las interacciones farmaco-farmaco.
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
WO2007143038A1 (en) * 2006-05-30 2007-12-13 Trustees Of Columbia University In The City Of New York Method of mediating airway smooth muscle construction due to airway irritation
WO2008008492A2 (en) * 2006-07-13 2008-01-17 University Of Iowa Research Fdtn. Hydrofluoroalkyl phenols having anesthetic properties
WO2008080047A2 (en) * 2006-12-23 2008-07-03 Baxter International Inc. Magnetic separation of fine particles from compositions
BRPI0811284A2 (pt) * 2007-05-09 2015-01-20 Pharmacofore Inc Compostos terapêuticos
PL2146946T3 (pl) * 2007-05-09 2011-04-29 Pharmacofore Inc (-)-Stereoizomer 2,6-di-sec-butylofenolu i jego analogi
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US20090198145A1 (en) * 2008-02-06 2009-08-06 Chow Harrison Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
US20180022698A1 (en) 2014-10-16 2018-01-25 The Board Of Trustees Of The Leland Stanford Junior University Novel methods, compounds, and compositions for anesthesia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2104412A (en) * 1931-12-29 1938-01-04 Standard Oil Dev Co Alkyl phenols
GB831071A (en) 1956-04-26 1960-03-23 British Schering Ltd Analgesic compounds
GB803080A (en) 1956-07-06 1958-10-15 Scient Oil Compounding Co Inc Bacteriostatic compositions
US2966442A (en) * 1956-09-20 1960-12-27 American Home Prod Antibiotic compositions
US3476838A (en) * 1958-12-04 1969-11-04 Ethyl Corp Di(2,6-diisopropylphenyl) mono halo phosphite or (thio) phosphate
US3067106A (en) * 1959-04-07 1962-12-04 Foundation For Prosthetic Res Skin treating method and composition

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19509828A1 (de) * 1994-03-22 1996-09-19 Zeneca Ltd Pharmazeutische Zusammensetzungen
US8206746B2 (en) 1996-08-22 2012-06-26 Jagotec Ag Microparticles of water-insoluble substances
US8415329B1 (en) 1998-05-29 2013-04-09 Jagotec Ag Thermoprotected compositions and process for terminal steam sterilization of microparticle preparations
US7939106B2 (en) 1998-11-20 2011-05-10 Jagotec Ag Process for preparing a rapidly dispersing solid drug dosage form
US7939105B2 (en) 1998-11-20 2011-05-10 Jagotec Ag Process for preparing a rapidly dispersing solid drug dosage form
US6634576B2 (en) 2000-08-31 2003-10-21 Rtp Pharma Inc. Milled particles
US8703202B2 (en) 2000-09-20 2014-04-22 Jagotec Ag Coated tablets

Also Published As

Publication number Publication date
JPS50154410A (US07902200-20110308-C00004.png) 1975-12-12
FR2265357B1 (fr) 1978-08-04
CA1038764A (en) 1978-09-19
MY8100111A (US07902200-20110308-C00004.png) 1981-12-31
FR2265357A1 (fr) 1975-10-24
IL46899A0 (en) 1975-06-25
SE7503542L (US07902200-20110308-C00004.png) 1975-09-29
US4452817A (en) 1984-06-05
FI750941A (US07902200-20110308-C00004.png) 1975-09-29
IE40839L (en) 1975-09-28
NL7503696A (nl) 1975-09-30
BE827290A (fr) 1975-09-29
IE40839B1 (en) 1979-08-29
NL183079C (nl) 1988-07-18
ZA751806B (en) 1976-02-25
NL930084I2 (nl) 1994-10-17
IL46899A (en) 1978-03-10
DOP1980002892A (es) 1989-10-04
NZ177023A (en) 1984-09-28
AU7953675A (en) 1976-09-30
PH13553A (en) 1980-06-26
DK128675A (de) 1975-09-29
US4056635A (en) 1977-11-01
HK34380A (en) 1980-07-01
NO751076L (US07902200-20110308-C00004.png) 1975-09-30
GB1472793A (en) 1977-05-04
NL930084I1 (nl) 1993-09-16
KE3052A (en) 1980-06-27
AU502164B2 (en) 1979-07-12
DE2513797A1 (de) 1975-10-09

Similar Documents

Publication Publication Date Title
DE2513797C2 (de) Pharmazeutische zusammensetzung
DE60028384T2 (de) Propofol enthaltende anästhetische zusammensetzung zur intravenösen injektion
US4798846A (en) Pharmaceutical compositions
DE69936911T2 (de) Propofolhaltiges arzneimittel enthaltend sulfite
DE4117249C2 (de) Linsidomin zur Behandlung erektiler Dysfunktionen
DE69535570T2 (de) Antimykotische Zusammensetzung zur äusserlichen Anwendung, die im Stratum Corneum retentiv ist
CH693764A5 (de) Pharmazeutische Zusammensetzung enthaltend Propofol und Edetat.
DE60308888T2 (de) Injizierbare 2,6-diisopropylphenol enthaltende anästhetische zusammensetzung und verfahren
DE60107272T2 (de) Eisenverbindungen
DE2631947A1 (de) Konservierung von basischen arzneimittelzubereitungen
EP0453603B1 (de) Piroxicam enthaltende pharmazeutische Zusammensetzung zur topischen Anwendung
EP0277462B1 (de) Verfahren zur Herstellung nasaler Lösungen enthaltend synthetisches Human calcitonin.
DE3634755A1 (de) Dermale behandlung von wurmerkrankungen der katze mit praziquantel
EP0450123B1 (de) Diclofenac-Natrium enthaltende pharmazeutische Zusammensetzung zur topischen Anwendung
DE60101979T2 (de) Lösung enthaltend N-[O-(p-pivaloyloxybenzenesulfonylamino)benzoyl]glyzin Mononatriumsalz Tetrahydrat und diese Lösung enthaltendes Arzneimittel
DE60100666T2 (de) Tierärztliche zusammensetzungen zur behandlung von parasiterkrankungen
DE69922252T2 (de) Parenterale lösungen enthaltend propofol (2,6-diisopropylphenol) und 2.5-di-0-methyl-1.4;3.6-dianhydro-d-glucitol als lösungsmittel
DE4220616C2 (de) Dexniguldipin zur intravenösen Verabreichung
WO2008138459A2 (de) Wässrige pharmazeutische zubereitung
DE2723936A1 (de) Ophthalmische loesung fuer die glaucom-behandlung
DE60304458T2 (de) Verwendung eines l-ascorbinsäuresalzes zur herstellung einer pharmazeutischen zusammensetzung für die ophthalmische topische anwendung zur verbesserung des l-ascorbinsäurespiegels im auge
DE68902792T2 (de) Mittel zur kosmetischen oder pharmazeutischen verwendung.
DE1617653B1 (de) Indomethacinpraeparat zur externen Anwendung
DE69534696T2 (de) Parenterale Fettemulsionen, die EDTA als Konservierungsmittel enthalten
DE2312134A1 (de) Anthelmintikum

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
D2 Grant after examination
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ZENECA LTD., LONDON, GB

8328 Change in the person/name/address of the agent

Free format text: ANDRAE, S., DIPL.-CHEM. DR.RER.NAT., 81541 MUENCHEN FLACH, D., DIPL.-PHYS., 83022 ROSENHEIM HAUG, D., DIPL.-ING. KNEISSL, R., DIPL.-CHEM. DR.RER.NAT., PAT.-ANWAELTE, 81541 MUENCHEN